The Technical AnalystExchange: OTC Sector: Healthcare Industry: Biotechnology
Vicapsys Life Sciences, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.990
America/New_York / 1 mai 2024 @ 10:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 31.75 mill |
| EPS: | -0.0300 |
| P/E: | -33.00 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 32.07 mill |
| Avg Daily Volume: | 0.0001 mill |
| RATING 2024-05-01 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -33.00 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -33.00 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0005 (-99.95%) $-0.989 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.949 - 1.031 ( +/- 4.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2010-09-03 | Yurkowski Michael | Sell | 5 000 | SSGI |
| 2010-08-09 | Yurkowski Michael | Sell | 20 000 | Common Stock |
| 2010-05-13 | Moore Bobby M Jr | Sell | 0 | Common Stock |
| 2010-01-26 | Yurkowski Michael | Sell | 5 000 | SSGI |
| 2010-01-14 | Yurkowski Michael | Sell | 5 000 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 19 transactions |
| Buy: 0 | Sell: 1 754 181 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.990 (0.00% ) |
| Volume | 0.0012 mill |
| Avg. Vol. | 0.0001 mill |
| % of Avg. Vol | 1 518.29 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VICP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VICP
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field. The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.